Robert A. Arthur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert A. Arthur has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Adam I. Marcus
Department of Hematology and Medical Oncology, Emory University, Atlanta, USA
27 shared publications - Henry Claussen
Emory Integrated Computational Core, Emory University School of Medicine, Atlanta, Georgia
27 shared publications - Henry Richard Johnston
Emory Integrated Computational Core Emory University Atlanta Georgia U.S.A.
27 shared publications - Amy Herrera
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia
26 shared publications - Ashok Reddy Dinasarapu
Department of Neurology, Emory University School of Medicine , Atlanta, GA 30322
26 shared publications - Bhakti Dwivedi
Winship Cancer Institute, Emory University, Atlanta, GA, USA
26 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Biosocial influences of gender identity and geography on mucosal microbial phenotypes
Background: Transgender women (TGW) experience unique hormonal contexts and high HIV incidence, yet the mucosal microbiome among TGW remains understudied. Sex hormones and geography may shape microbial composition, but the relative contributions of gender identity, feminizing hormone therapy (FHT), and location are unclear. Methods: We conducted a multi-site study of TGW using FHT and cisgender men who have sex with men (MSM), all without HIV, in Atlanta, USA ( n = 58; 25 TGW, 33 MSM) and Bangkok, Thailand ( n = 147; 97 TGW, 50 MSM)( n = 205). We also conducted longitudinal sampling in 21 TGW pre/post FHT initiation. Rectal swabs were collected from all participants, with optional neovaginal sampling in TGW. Microbiota composition was analyzed using 16S rRNA sequencing, and associations with gender category, geography, and hormone concentrations were assessed using linear decomposition modeling (LDM) and BOUTH analysis. Results: Here we show that the rectal microbiota differ significantly by both gender category and geography. TGW exhibit enrichment of estrogen-metabolizing taxa across sites, while MSM show Prevotellaceae enrichment in Atlanta only. Alpha diversity varies by location but not gender category. Neovaginal microbiota differ markedly from rectal composition, showing enrichment of skin- and gut-associated taxa and anaerobic taxa associated with HIV seroconversion. No significant rectal microbiota shifts are observed after short-term FHT initiation, possibly reflecting subtherapeutic hormone exposure. Conclusions: These findings underscore the need to consider gender identity as a complex biosocial phenotype in HIV prevention and highlight the potential role of mucosal microbiota in shaping HIV vulnerability in TGW.
- 14 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessBiosocial influences of gender identity and geography on mucosal microbial phenotypes
Background: Transgender women (TGW) experience unique hormonal contexts and high HIV incidence, yet the mucosal microbiome among TGW remains understudied. Sex hormones and geography may shape microbial composition, but the relative contributions of gender identity, feminizing hormone therapy (FHT), and location are unclear. Methods: We conducted a multi-site study of TGW using FHT and cisgender men who have sex with men (MSM), all without HIV, in Atlanta, USA ( n = 58; 25 TGW, 33 MSM) and Bangkok, Thailand ( n = 147; 97 TGW, 50 MSM)( n = 205). We also conducted longitudinal sampling in 21 TGW pre/post FHT initiation. Rectal swabs were collected from all participants, with optional neovaginal sampling in TGW. Microbiota composition was analyzed using 16S rRNA sequencing, and associations with gender category, geography, and hormone concentrations were assessed using linear decomposition modeling (LDM) and BOUTH analysis. Results: Here we show that the rectal microbiota differ significantly by both gender category and geography. TGW exhibit enrichment of estrogen-metabolizing taxa across sites, while MSM show Prevotellaceae enrichment in Atlanta only. Alpha diversity varies by location but not gender category. Neovaginal microbiota differ markedly from rectal composition, showing enrichment of skin- and gut-associated taxa and anaerobic taxa associated with HIV seroconversion. No significant rectal microbiota shifts are observed after short-term FHT initiation, possibly reflecting subtherapeutic hormone exposure. Conclusions: These findings underscore the need to consider gender identity as a complex biosocial phenotype in HIV prevention and highlight the potential role of mucosal microbiota in shaping HIV vulnerability in TGW.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Legends for Supplementary Figures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Legends for Supplementary Figures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
List of upregulated transcripts in KL vs. KP invasive spheroids with respect to K>C.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
List of upregulated transcripts in KL vs. KP invasive spheroids with respect to K>C.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Invasive phenotyping of K, KL, and KP HBECs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Invasive phenotyping of K, KL, and KP HBECs
- Open Access
- 1 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0317972
Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA
While SARS-CoV-2 vaccines have shown strong efficacy, the continued emergence of new viral variants raises concerns about the ongoing and future public health impact of COVID-19, especially in locations with suboptimal vaccination uptake. We investigated viral and host factors, including vaccination status, that were associated with SARS-CoV-2 disease severity in a setting with low vaccination rates. We analyzed clinical and demographic data from 1,957 individuals in the state of Georgia, USA, coupled with viral genome sequencing from 1,185 samples. We found no specific mutations associated with disease severity. Compared to those who were unvaccinated, vaccinated individuals experienced less severe SARS-CoV-2 disease, and the effect was similar for both variants. Vaccination within the prior 3-9 months was associated with decreased odds of moderate disease, severe disease, and death. Older age and underlying health conditions, especially immunosuppression and renal disease, were associated with increased disease severity. Overall, this study provides insights into the impact of vaccination status, variants/mutations, and clinical factors on disease severity in SARS-CoV-2 infection when vaccination rates are low. Understanding these associations will help refine and reinforce messaging around the crucial importance of vaccination in mitigating the severity of SARS-CoV-2 disease.
- 1 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0317972
Open AccessViral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA
While SARS-CoV-2 vaccines have shown strong efficacy, the continued emergence of new viral variants raises concerns about the ongoing and future public health impact of COVID-19, especially in locations with suboptimal vaccination uptake. We investigated viral and host factors, including vaccination status, that were associated with SARS-CoV-2 disease severity in a setting with low vaccination rates. We analyzed clinical and demographic data from 1,957 individuals in the state of Georgia, USA, coupled with viral genome sequencing from 1,185 samples. We found no specific mutations associated with disease severity. Compared to those who were unvaccinated, vaccinated individuals experienced less severe SARS-CoV-2 disease, and the effect was similar for both variants. Vaccination within the prior 3-9 months was associated with decreased odds of moderate disease, severe disease, and death. Older age and underlying health conditions, especially immunosuppression and renal disease, were associated with increased disease severity. Overall, this study provides insights into the impact of vaccination status, variants/mutations, and clinical factors on disease severity in SARS-CoV-2 infection when vaccination rates are low. Understanding these associations will help refine and reinforce messaging around the crucial importance of vaccination in mitigating the severity of SARS-CoV-2 disease.